BNP Paribas Asset Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $290K | Buy |
|
|||||
|
2025
Q1 | $225K | Sell |
|
|||||
|
2024
Q4 | $852K | Sell |
|
|||||
|
2024
Q3 | $28.1M | Sell |
|
|||||
|
2024
Q2 | $42.6M | Buy |
|
|||||
|
2024
Q1 | $55.3M | Sell |
|
|||||
|
2023
Q4 | $60.2M | Buy |
|
|||||
|
2023
Q3 | $49.6M | Buy |
|
|||||
|
2023
Q2 | $42.2M | Buy |
|
|||||
|
2023
Q1 | $33.8M | Sell |
|
|||||
|
2022
Q4 | $42.7M | Buy |
|
|||||
|
2022
Q3 | $34.1M | Sell |
|
|||||
|
2022
Q2 | $41M | Buy |
|
|||||
|
2022
Q1 | $52.8M | Buy |
|
|||||
|
2021
Q4 | $65.4M | Buy |
|
|||||
|
2021
Q3 | $65.9M | Buy |
|
|||||
|
2021
Q2 | $57.5M | Sell |
|
|||||
|
2021
Q1 | $58.9M | Sell |
|
|||||
|
2020
Q4 | $51.6M | Buy |
|
|||||
|
2020
Q3 | $45.5M | Buy |
|
|||||
|
2020
Q2 | $28.2M | Buy |
|
|||||
|
2020
Q1 | $18.2M | Buy |
|
|||||
|
2019
Q4 | $19.5M | Sell |
|
|||||
|
2019
Q3 | $17.9M | Sell |
|
|||||
|
2019
Q2 | $19.3M | Sell |
|
|||||
|
2019
Q1 | $22.5M | Buy |
|
|||||
|
2018
Q4 | $17.3M | Buy |
|
|||||
|
2018
Q3 | $19.6M | Sell |
|
|||||
|
2018
Q2 | $17.3M | Buy |
|
|||||
|
2018
Q1 | $15.4M | Buy |
|
|||||
|
2017
Q4 | $15.2M | Sell |
|
|||||
|
2017
Q3 | $15.6M | Buy |
|
|||||
|
2017
Q2 | $14.5M | Sell |
|
|||||
|
2017
Q1 | $19.1M | Sell |
|
|||||
|
2016
Q4 | $19.8M | Buy |
|
|||||
|
2016
Q3 | $17.1M | Sell |
|
|||||
|
2016
Q2 | $19.7M | Buy |
|
|||||
|
2016
Q1 | $3.88M | Buy |
|
|||||
|
2014
Q1 | – | Sell |
|
|||||
|
2013
Q4 | $509K | Hold |
|
|||||
|
2013
Q3 | $444K | Sell |
|
|||||
|
2013
Q2 | $11.2M | Buy |
|